Taysha Gene Therapies, Inc. TSHA 深 滬
等待開盤 11-26 09:30:00 美东时间
4.59
+0.170
+3.85%
華盛通- 最 高4.60
- 今 開4.44
- 成交量 345.05万股
- 最 低 4.34
- 昨 收 4.42
- 總市值 12.58亿
- 52周最高 5.5082
- 市盈率 靜 --
- 換手率 1.26%
- 52周最低 1.05
- 委 比 -96.78%
- 總股本 2.74亿
- 歷史最高 33.35
- 量 比 0.90
- 振 幅 5.88%
- 歷史最低 0.50
- 每 手 1
- 風險率 1.01%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
11-06 09:55
Chardan Capital Maintains Buy on Taysha Gene Therapies, Maintains $12 Price Target
Chardan Capital analyst Geulah Livshits maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and maintains $12 price target.
11-05 20:40
Taysha Gene Therapies Q3 EPS $(0.09), Inline. Revenue $0. Cash And Equivalents $299.94M.
Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is a 10 percent increase over losses of $(0.10) per share from the same period last year.
11-04 19:58
Earnings Scheduled For November 4, 2025
Companies Reporting Before The Bell • Sequans Communications (NYSE:SQNS) is lik...
11-04 19:12
美股大行评级 | 富国银行上调苹果目标价升至290美元；"卖出"！花旗下调NuScale Power、阿特斯太阳能评级
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从30美元升至44美元；Piper Sandler：维持Vital Energy"中性"评级，目标价从16美元升至30美元
10-22 10:10
美股大行评级 | 潜在最高涨幅37.45%，甲骨文获多家机构上调目标价；瑞穗上调美光科技目标价升至240美元
今日重点评级关注：韦德布什：维持Artiva Biotherapeutics"跑赢大市"评级，目标价从18美元升至23美元；巴克莱：维持Cellectis"超配"评级，目标价从4美元升至8美元
10-20 10:03
Taysha Gene Therapies Regains Full Rights To Its Lead TSHA-102 Program In Clinical Evaluation For Rett Syndrome; TSHA-102 Has Demonstrated Compelling Part A REVEAL Phase 1/2 Safety And Efficacy Data, Received FDA Breakthrough Therapy Designation And Is Advancing With A Clear Path To Potential Registration
DALLAS, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies
10-17 04:06
Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome
<p>Taysha Gene Therapies announced the expiration of its 2022 Option Agreement with Astellas Pharma, regaining full rights to its TSHA-102 program for Rett syndrome. The program has shown promising safety and efficacy data, receiving FDA Breakthrough Therapy designation. dosing of the first patient in the pivotal REVEAL trial is scheduled this quarter. Taysha now has full strategic flexibility to advance TSHA-102 towards potential commercializati...
10-16 20:01
Taysha Gene Therapies Presents Promising TSHA-102 Data
Taysha Gene Therapies ( ($TSHA) ) just unveiled an announcement. On October 9, ...
10-09 20:44
Taysha Gene Announces Results From Supplemental Data Analysis From Part A Of REVEAL Phase 1/2 Adult/Adolescent And Pediatric Trials Evaluating TSHA-102 In Females With Rett Syndrome At CNS Annual Meeting
Previously disclosed 100% response rate across all 10 patients in Part A for pivotal trial primary endpoint of gain/regain of ≥ one natural history defined developmental milestone assessed via video-evidenced review by
10-09 20:04
